ReviewInternational journal of nanomedicine2025
Advances in Chondroitin Sulfate-Based Nanoplatforms for Biomedical Applications.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Spatial Profiling of Glycosaminoglycans (GAGomics) From Laser Microdissected Mouse Brain.Molecular & cellular proteomics : MCP · 2026Article
- Research landscape, hotspots, and evolutionary trends of knee osteoarthritis and oxidative stress: a multidimensional bibliometric analysis.Frontiers in medicine · 2026Article
- Ligand-modified multifunctional liposome-based targeted delivery platform: a multimodal cancer combination therapy strategy.Theranostics · 2026Review
- Chondroitin Sulfate-Based Nanoplatforms: Advances and Challenges for Cancer Therapy.Molecules (Basel, Switzerland) · 2025Review
- The impact of the conjugation manner of targeting agent and tandem cell-penetrating peptide on the efficacy of mitomycin C liposomes in treating triple-negative breast tumors.International journal of pharmaceutics: X · 2025Article
- Reduction-Responsive Nanoparticles Self-Assembled from Sericin-ss-Doxorubicin Conjugate for Hydrophobic IR780 Delivery with Integration of Antitumor Chemo-Phototherapy.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chondroitin sulfate (CS) is a naturally sulfated glycosaminoglycan with diverse biofunctional properties, including anti-inflammatory effects, reactive oxygen species scavenging, cartilage regeneration and immune regulation. In recent years, CS has shown significant progress in biomedical applications, particularly in drug delivery, tissue engineering, and biosensing. This paper reviews the latest advancements of CS-based nanoplatforms in the biomedical field. CS can be integrated with functional molecules to construct a variety of nanostructures, further expanding its potential applications. CS exhibits distinctive characteristics, and CS-based nanoparticles could serve as promising drug delivery vehicles in tumor therapy. Beyond their roles in drug delivery, CS-based nanoplatforms exhibit transformative potential in tissue engineering, offering promising solutions for wound repair and tissue regeneration. Additionally, CS enhances early disease diagnostics through biomarker detection, leveraging its unique molecular structure and biocompatibility. This comprehensive review explored the properties of CS-based nanoplatforms and their diverse applications, aiming to provide a reference for related research and encourage further advancements in the biomedical fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.